As per Market Research Future Analysis, the Global Necrotizing Fasciitis Market was valued at USD 0.26 Billion in 2023 and is projected to grow to USD 2.43 Billion by 2032, with a CAGR of 6.81% from 2024 to 2032. This rare bacterial infection, also known as flesh-eating disease, primarily affects tissue beneath the skin and can be life-threatening if untreated. Major risk factors include diabetes, cancer, and obesity. The market is driven by the increasing prevalence of these conditions and the aging population, while growth is hindered by a lack of awareness and high treatment costs.
The necrotizing fasciitis market is characterized by significant growth drivers and challenges.
Merck & Co. (U.S.), WOCKHARDT (India), Atox Bio (Israel), Teva Pharmaceutical Industries (Israel), Basilea Pharmaceutica Ltd. (Switzerland), MELINTA THERAPEUTICS, INC. (U.S.)
Also known as flesh-eating disease, necrotizing fasciitis is a rare bacterial infection affecting the tissue beneath the skin, surrounding muscles, and organs. The bacteria that is responsible for the disease releases toxins results into the damage nearby tissue.
There are four major types for necrotizing fasciitis – type I known as polymicrobial infection, type II caused by haemolytic group A streptococcus, staphylococci such as methicillin resistant strains/MRSA, type III caused by bacterium such as clostridium, and others. It starts as a minor injury such as a small cut, but may get worst and can be life threatening if left untreated. Major risk factors for the disease are diabetes, cancer, obesity, intravenous drug use, alcoholism, and peripheral vascular disease. The disease can be prevented by maintaining hygiene which includes proper wound care and hand washing.
The necrotizing fasciitis market is majorly driven by the increasing prevalence of cancer, diabetes, continuously increasing geriatric population and increasing number of patients suffering from various bacterial infection. However, the growth of the necrotizing fasciitis market is restricted due to lack of awareness about necrotizing fasciitis and high cost of treatment.
America accounts for the largest share in the necrotizing fasciitis market owing to presence of key players in the necrotizing fasciitis market and rising emphasis on diagnosis and treatment of rare diseases. Furthermore, rising awareness about bacterial infection is further set to accelerate the growth of the necrotizing fasciitis market. North America is the accounted for the highest market share in this region with the U.S. being the largest market followed by Canada. In the U.S, the prevalence of cardiovascular disease is found to be increasing from last few years. This is attributed to the rising prevalence of chronic diseases such as obesity and diabetes which are the major risk factors for cardiovascular diseases. As per the Center for Disease Control & Prevention (CDC), in 2015, 28.4 million adults were diagnosed with cardiovascular diseases in the U.S. alone.
Europe is the second largest market and holds a noticeable share in the necrotizing fasciitis market. The European market is expected to grow significantly during the forecast period owing to availability of advanced treatment facilities and skilled medical professionals. Furthermore, extensive research and development activities for the treatment of rare disease and increasing government support.
Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases such as diabetes, cancer and bacterial infection in developing countries is the major driver for the market growth. China and India are the fastest growing regions owing to increasing geriatric population. Also, the diabetes is one of the major chronic conditions affecting large number of patients, thereby influencing the market growth. Rising awareness about the infections and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and overall growth of healthcare diagnostic and treatment industry also drive the market. According to the International Diabetic Federation, about 415 million people had diabetes across the globe in 2015, which is expected to reach 642 million by 2040. It also stated that 98.4 million and 65.1 million diabetic population lived in China and India, respectively. It stated that in 2015, 3.7% of the Asian population was diagnosed with chronic heart disease, while 21% of the population had hypertension
The Middle East & Africa is expected to show the least growth in the necrotizing fasciitis market due to some major factors such as lack of awareness about necrotizing fasciitis, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates holds the largest market share owing to development of healthcare industry and rising availability of specialty care centers.
Some of the key players in necrotizing fasciitis market are:Â
Intended Audience
| Attribute/Metric | Details |
| Market Size 2023 | 0.26 (USD Billion) |
| Market Size 2024 | 0.54 (USD Billion) |
| Market Size 2032 | 2.43 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 6.81 % (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Â Â Merck & Co. (U.S.), WOCKHARDT (India), Atox Bio (Israel), Teva Pharmaceutical Industries (Israel), Basilea Pharmaceutica Ltd. (Switzerland), and MELINTA THERAPEUTICS, INC. (U.S.) |
| Â Â Key Market Opportunities | Â Â New product launches and R&D Amongst major key Players |
|   Key Market Drivers | · Increasing prevalence of cancer, diabetes, continuously · Increasing geriatric population · Increasing number of patients suffering from various bacterial infection |
Necrotizing Fasciitis Market Highlights:
Frequently Asked Questions (FAQ):
Necrotizing fasciitis market is expected to expand at 6.81% CAGR from 2024 to 2032.
Necrotizing fasciitis market is driven by large number of patients affected by bacterial infections, large geriatric populace, and prevalence of non-communicable diseases.
Necrotizing fasciitis market is restrained by lack of awareness of the disease.
APAC can display a robust growth rate in the necrotizing fasciitis market.
WOCKHARDT, MELINTA THERAPEUTICS, INC. Basilea Pharmaceutica Ltd., Teva Pharmaceutical Industries, Merck & Co., and Atox Bio are key players of the necrotizing fasciitis market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
